Clinical and Functional Effects of Cardiac Contractility Modulation in Chagas Heart Disease a Randomized Study comparing CCM and CRT devices

What this Trial Is About

Chagas disease is a widespread condition in Latin America caused by the parasite Trypanosoma cruzi, affecting millions and leading to chronic Chagas cardiomyopathy CCC in 30-50 of cases. This serious heart condition often results in heart failure and high rates of illness and death. The trial investigates whether cardiac contractility modulation CCM devices provide better clinical and functional benefits compared to cardiac resynchronization therapy CRT for patients with advanced heart failure and CCC who do not have left bundle branch block. The study involves two groups one receiving CCM device implantation and the other undergoing CRT implantation. CCM delivers high-tension electrical stimulation to improve heart muscle contraction during a specific phase of the heartbeat. The trial compares these two device-based treatments to evaluate their impact on heart function and patient quality of life. Participants will be monitored over six months with assessments including quality of life scores, heart strain measurements, functional capacity tests like the 6-minute walk test, heart failure classification, and hospitalization records. The study tracks these measures at the start and after six months to determine the effects of the treatments on heart performance and daily functioning in patients with CCC and severe heart failure.

Cardiac Contractility Modulation in Chagas Heart Disease